Adherex and Scynexis Sign Agreement to Accelerate Design of Small Molecule Cadherin Antagonists

• Published in: Marketwire p. 1
• Format: Trade Publication Article
• Language: English
• Published: Toronto Intrado Digital Media Canada Inc 23.03.2005

Dr. Brian Huber, Adherex's Chief Scientific Officer, explained the goals behind this agreement. "Adherex's lead biotechnology compound, ADH-1, is progressing well through its development and is entering Phase II clinical trials. ADH-1 is a cyclic peptide that has been well tolerated and has shown encouraging anti-tumor activity in our Phase I program. It is administered by intravenous injection, which is appropriate for an anti-tumor and vascular targeting agent used in cancer patients. However, there are other potential uses for cadherin antagonist drugs that would be better served by an orally active drug. To enhance our capabilities for oral drug delivery, we are working with SCYNEXIS to expand our small molecule discovery efforts." This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of Adherex might differ materially from the results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the drug development plans of Adherex, both alone and through the agreement with SCYNEXIS, as well as the expected benefits, timing and results. Adherex can provide no assurance that the development plans will proceed as currently anticipated or that expected benefits, timing or results will be realized. Adherex is subject to risks inherent in the biopharmaceutical industry, including the early stage of its product candidates, its reliance on collaborations and its history of losses. For a more detailed discussion of related risk factors, please refer to Adherex's public filings available at www.sedar.com and www.sec.gov.